Dr. Powderly Discusses TILs and Cell and Gene Therapy on the “TIL Talks” Podcast
TIL Talks by Chris White – 7/28/25
Listen to Dr. Powderly as he talks with podcast host Chris White about advancements in immunotherapy, with a focus on Peripheral Tumor Infiltrating Lymphocytes (TILs) and their potential for use in cancer treatment. Chris White is a Mucosal Melanoma survivor who has created the podcast called “TIL Talks”, in which he holds one-on-one conversations with patient recipients, caregivers, and industry leaders who have experienced first-hand the curative possibilities of TILs and/or cell and gene therapies. Over the next few months, Dr. Powderly and Chris White will engage in a total of four conversations.
You can hear the first one on YouTube or Spotify using the links below. Look for Episode #12. Then, come back to our News section over the next few weeks to access new links as the next interviews get released.
In this first session, Dr. Powderly discusses his experience as an oncologist and the efforts and clinical trials that are ongoing at Carolina BioOncology. He and Chris then discuss the importance of cell therapy and the need for expanded access to clinical trials. They also highlight the importance of patient advocacy and patients being active in their own care efforts. Finally, they discuss the future of cancer therapies.
Advancing Cancer Research Through Global Collaboration
AbbVie – 5/29/25
Carolina BioOncology Institute is honored to be selected to be part of AbbVie’s Phase I Partnerships for Excellence in Research (P1PER) network, P1PER is AbbVie’s global network of leading clinical trial centers in oncology, designed to accelerate early development of novel therapies across difficult-to-treat blood cancers and solid tumors. P1PER was created to further advance and accelerate cancer research and foster groundbreaking collaboration and innovation. Our participation reflects a shared commitment to innovation, collaboration, and delivering meaningful progress for patients in need. Click the link below to learn more about this important partnership and our contribution to the future of cancer care.
AABB-Accredited Facility Biotherapies Services Spotlight Series February 2025: Carolina BioOncology Institute
AABB – 2/1/25
In 2005, John Powderly, MD, founded both CBOI and BioCytics as reflections of the same vision to deliver autologous immune cell therapies manufactured at the point of care for early phase clinical trials. He states that, “We believe the future of bespoke regenerative medicine depends upon regional human application labs as an efficient, affordable and accessible delivery system. Our recent AABB accreditation is another step closer to realizing our vision to enable future cellular immune cures for solid tumor cancer patients.”
National Minority Quality Forum’s announces a collaboration with Carolina BioOncology Institute
NMQF By Adjoa Kyerematen – 10/24/24
NMQF, Carolina BioOncology, and BioCytics are collaborating to create a national registry and biorepository for CSSI, collecting critical clinical, genetic, and demographic data from 20 communities. This biorepository will support research on cancer risk factors, driving logistical changes to ease the development and deployment of new detection technologies and precision treatments. De-identified data will be accessible to researchers, helping ensure that advancements in cancer care reach underserved communities. The findings will be used to improve local cancer care logistics, advancing the Cancer Moonshot’s goal of reducing cancer mortality in these populations by addressing bottlenecks through a data-driven approach.
Highlights from the September 9th Event: UNC Charlotte Dubois Center Through NCBiotech
The Center for Biomedical Engineering and Science – 9/9/24
Featured Practice: Carolina BioOncology Institute & BioCytics Human Applications Lab
Charlotte Mag Content Studio – 7/1/24
